The use of the highly potent, IKKβ-activated, RNA-loaded designer DCs (3rd generation DCs) as adjuvant, combined with an individual selection of tumor neo-antigens and overexpressed antigens in this first-in-human trial holds great promise. The gene discussed is IKBKB; the disease is neoplasm.